Biological Effects of LEO 43204 in Actinic Keratosis Assessed by Histopathology
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Ingenol disoxate (Primary)
- Indications Actinic keratosis
- Focus Pharmacodynamics
- Sponsors LEO Pharma
- 10 Jun 2017 Biomarkers information updated
- 02 Mar 2017 Status changed from recruiting to completed.
- 15 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 May 2017.